Avita Medical, Inc. (RCEL) Stock Price & Analysis
Avita Medical, Inc. (RCEL) rose 2.38% to USD 11.2 as of September 8, 2026 at 13:22 UTC, according to Nexqual real-time market data.
RCEL last closed at USD 11.2; the session ranged USD 10.8–11.39 on volume of 301,850 shares. Market capitalization is —, with a 52-week range of USD 3.22–11.39 (NCM). Source: Nexqual, September 8, 2026 at 13:22 UTC.
Key Statistics (as of September 8, 2026 at 13:22 UTC)
| Price | USD 11.2 |
|---|---|
| Change | ▲ 2.38% (up) |
| Previous Close | USD 11.2 |
| Open | USD 11.2 |
| Day Range | USD 10.8 – 11.39 |
| 52-Week Range | USD 3.22 – 11.39 |
| Volume | 301,850 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (RCEL)
Nexqual's technical model rates RCEL "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 13:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 77.72 (overbought) |
| vs SMA50 | Above (USD 6.69) |
| MACD | 1.28 (positive) |
From Avita Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- RECELL (including RECELL GO) has received CE-mark approval in Europe; RECELL, excluding RECELL GO, has received PMDA approval for burns in Japan and is TGA-registered in Australia.   HEALTHCARE LAWS AND REGULATIONS AVITA Medical is a manufacturer of medical devices, and therefore we are subject to regulations by the FDA and various federal and state healthcare laws and regulations.
- Our commercial success also depends in part on our ability to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
- This indication materially expands our addressable market and allows us to leverage our existing commercial infrastructure and clinical relationships.
Partnerships
- In July 2024, we entered into an exclusive multi-year development and distribution agreement with Collagen Matrix, LLC d/b/a as Regenity Biosciences ("Regenity"), granting us exclusive rights to market, sell, and distribute Cohealyx, an AVITA-medical branded collagen-based dermal matrix in the U.S., with potential expansion into the European Union ("E.U."), Australia, and Japan.
- In January 2024, we entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. ("Stedical") to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix in the United States ("U.S.").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SIBN | SI-BONE, Inc. | USD 18.5 | ▼ 3.44% |
| TELA | TELA Bio, Inc. | USD 0.82 | ▲ 9.31% |
| LUNG | Pulmonx Corporation | USD 2.21 | ▼ 3.07% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 12.86 | ▼ 2.06% |
| PROF | Profound Medical Corp. | USD 6.89 | ▲ 1.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 13:22 UTC. This page is informational and not investment advice.